Skip to content

Effects of Different Concentrations of Liposomal Bupivacaine for Fascia Iliaca Compartment Block on Postoperative Analgesia in Hip Fracture Surgery

Effects of Different Concentrations of Liposomal Bupivacaine for Fascia Iliaca Compartment Block on Postoperative Analgesia in Hip Fracture Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118138
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip arthroplasty

Interventions

High concentration group:20 mL of bupivacaine liposome plus 10 mL of normal saline was administered during ultrasound-guided block.
Low concentration group:Bupivacaine liposome 10mL plus normal saline 20mL was administered during ultrasound-guided nerve block.
Medium concentration group:15 mL of bupivacaine liposome plus 15 mL of normal saline was administered during ultrasound-guided block.

Sponsors

No.215 Hospital of Shaanxi Nuclear Industry
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.18–80 years of age, ASA ?-?; 2.Patients diagnosed with femoral neck fracture, femoral head necrosis, or hip osteoarthritis, who are candidates for elective unilateral total hip arthroplasty. 3.Absence of a history of local anesthetic allergy and severe hepatic or renal dysfunction. 4.The patient and their family have been informed and have signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Infection at the puncture site, abnormal coagulation function (such as INR > 1.5); 2.Severe neuropathy (such as sciatic nerve injury; 3.Cognitive impairment, unable to cooperate with pain assessment; 4.Patients who have used long-acting local anesthetics or have allergies to opioid drugs in the past month;

Design outcomes

Primary

MeasureTime frame
Pain Rating;

Secondary

MeasureTime frame
Adverse reaction;Rehabilitation indicators;Security metrics;Opioid Use;

Countries

China

Contacts

Public ContactJiang Liuqin

No.215 Hospital of Shaanxi Nuclear Industry

jlq215hp@163.com+86 29 32088348

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026